SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

Study Identifier:
ECU-COV-401
ClinicalTrials.gov Identifier:
NCT04355494
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Infections & Vaccines-Preventable Conditions - Other
  • Unmapped
Study Drug
  • Biological: eculizumab
Date
N/A - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Infections & Vaccines-Preventable Conditions - Other
  • Unmapped
Study Drug
  • Biological: eculizumab
Date
N/A - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

This protocol provides access to eculizumab treatment for participants with severe COVID-19.

Trial Locations

Location
Status
Location
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Status
N/A
Location
Boston Medical Center
Boston, Massachusetts, United States, 02118
Status
N/A
Location
Newton-Wellesley Hospital
Newton, Massachusetts, United States, 02462
Status
N/A
Location
Mayo Clinic
Rochester, Minnesota, United States, 55905
Status
N/A
Location
Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States, 08901
Status
N/A
Location
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Status
N/A